S1P/S1PRs‐TRPV4 axis is a novel therapeutic target for persistent pain and itch in chronic dermatitis
British Journal of Pharmacology · 2025
DOI: 10.1111/bph.17393 ↗At a glance
Journal article in British Journal of Pharmacology, 2025. Written by Xinyu Zhang and 14 co-authors. Institution: Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Jiangsu Key Laboratory for High Technology Research of TCM …. Major MEDLINE topics: Pruritus, TRPV Cation Channels, Lysophospholipids, Sphingosine. Cited 2 times so far (Crossref); 34 references. Funded by: Basic Research Program of Jiangsu Province, Open Project of Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, National Natural Science Foundation of China.
Abstract (original language)
Background and Purpose While pain and itch are both commonly associated with chronic dermatitis (CD), the molecular mechanisms underlying these debilitating symptoms is not well understood. This study aims to identify novel, endogenous compounds that mediate CD‐associated pain and itch. Experimental Approach Lesional skin of CD model mice was examined using unbiased metabolomic analysis to identify candidate pain or itch inducing compounds in CD. Sphingosine‐1‐phosphate (S1P) concentration in CD model skin was analysed using UPLC/MS/MS. Behaviour, calcium imaging and immunofluorescence staining were used to determine the pain and itch effects and mechanisms of the identified CD‐related compounds. Key Results In the lesional skin of CD model mice, 136 compounds were significantly changed. These compounds are predominately associated with the sphingolipids metabolism pathway. S1P is significantly increased in the lesional skin . The TRPV4 channel was critical for S1P induced itch and pain. Sphingosine kinase 2 (SPHK2), the key enzyme controlling S1P synthesis, was significantly increased in lesional skin. ABC294640, a SPHK2 inhibitor, significantly decreased S1P concentration in lesional CD model skin, as well as in model associated epidermal hyperplasia and chronic pain and itch. In CD patients, SPHK2 expression and S1P concentration were significantly elevated compared to healthy control skin. Conclusion and Implications Our results indicate that, in CD, increased S1P induces chronic pain and itch partly through TRPV4. Inhibition of S1P synthesis or the S1P/S1P receptor‐TRPV4 pathway are promising treatment strategies for CD‐associated pain and itch.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Jiangsu Key Laboratory for High Technology Research of TCM Formulae, Nanjing University of Chinese Medicine, Nanjing, China.
- Key Laboratory for Chinese Medicine of Prevention and Treatment in Neurological Diseases, School of Medicine, Nanjing University of Chinese Medicine, Nanjing, China.
- Department of Dermatology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
- School of Life Science, China Pharmaceutical University, Nanjing, China.
ORCID profiles: Guang Yu
Funding
- Basic Research Program of Jiangsu Province
- Open Project of Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization
- National Natural Science Foundation of China
- High level key discipline construction project of the National Administration of Traditional Chinese Medicine-Resource Chemistry of Chinese Medicinal Materials
Cite
APA
Zhang, X., Zhou, Y., Wang, C., Ren, J., Wang, Y., Liu, P., Feng, W., Li, X., Qi, M., Yang, Y., Zhu, C., Wang, F., Ma, Y., Tang, Z., & Yu, G. (2025). S1P/S1PRs‐TRPV4 axis is a novel therapeutic target for persistent pain and itch in chronic dermatitis. British Journal of Pharmacology. https://doi.org/10.1111/bph.17393
Vancouver
Zhang X, Zhou Y, Wang C, Ren J, Wang Y, Liu P, et al. S1P/S1PRs‐TRPV4 axis is a novel therapeutic target for persistent pain and itch in chronic dermatitis. British Journal of Pharmacology. 2025. doi:10.1111/bph.17393
BibTeX
@article{Zhang2025,
author = {Zhang, Xinyu and Zhou, Yuan and Wang, Changming and Ren, Jiahui and Wang, Yin and Liu, Pei and Feng, Weimeng and Li, Xue and Qi, Mingxin and Yang, Yan and Zhu, Chan and Wang, Fang and Ma, Yuxiang and Tang, Zongxiang and Yu, Guang},
title = {S1P/S1PRs‐TRPV4 axis is a novel therapeutic target for persistent pain and itch in chronic dermatitis},
journal = {British Journal of Pharmacology},
year = {2025},
doi = {10.1111/bph.17393}
}
EUVIMED